Minimally invasive glaucoma surgeries (MIGS) have emerged as a significant advancement in glaucoma treatment, offering a less invasive alternative to traditional surgeries. These procedures aim to reduce intraocular pressure (IOP), minimize tissue trauma, and provide a safer profile. MIGS include various techniques such as trabecular meshwork bypass, suprachoroidal shunts, and subconjunctival filtration, each targeting different aspects of aqueous humor dynamics. Devices like the Trabectome, iStent, Hydrus Microstent, XEN Gel Stent, and KDB have been developed to enhance outflow and reduce IOP. MIGS have shown efficacy in reducing IOP and medication use, with a favorable safety profile compared to traditional surgeries. However, challenges remain, including limited efficacy in severe cases, the need for long-term data, and issues of cost and accessibility. Ongoing research and technological innovations continue to refine MIGS, promising further improvements in glaucoma management. The global acceptance of MIGS is increasing, with a growing number of studies and clinical trials supporting their use. Despite their advantages, MIGS require careful patient selection and surgeon training to ensure optimal outcomes. The future of MIGS lies in continued research, development of new devices, and integration into comprehensive glaucoma treatment strategies.Minimally invasive glaucoma surgeries (MIGS) have emerged as a significant advancement in glaucoma treatment, offering a less invasive alternative to traditional surgeries. These procedures aim to reduce intraocular pressure (IOP), minimize tissue trauma, and provide a safer profile. MIGS include various techniques such as trabecular meshwork bypass, suprachoroidal shunts, and subconjunctival filtration, each targeting different aspects of aqueous humor dynamics. Devices like the Trabectome, iStent, Hydrus Microstent, XEN Gel Stent, and KDB have been developed to enhance outflow and reduce IOP. MIGS have shown efficacy in reducing IOP and medication use, with a favorable safety profile compared to traditional surgeries. However, challenges remain, including limited efficacy in severe cases, the need for long-term data, and issues of cost and accessibility. Ongoing research and technological innovations continue to refine MIGS, promising further improvements in glaucoma management. The global acceptance of MIGS is increasing, with a growing number of studies and clinical trials supporting their use. Despite their advantages, MIGS require careful patient selection and surgeon training to ensure optimal outcomes. The future of MIGS lies in continued research, development of new devices, and integration into comprehensive glaucoma treatment strategies.